Dusquetide for the Treatment of Behcet's Disease (NCT06386744) | Clinical Trial Compass
CompletedPhase 2
Dusquetide for the Treatment of Behcet's Disease
Turkey (Türkiye)8 participantsStarted 2024-11-18
Plain-language summary
This is a clinical study to see if dusquetide can treat flares of oral and genital ulcers caused by Behcet's Disease. Study participants will receive an infusion of dusquetide twice a week for 4 weeks (8 treatments total), with weekly follow-up visits for an additional 4 weeks.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Exclusion criteria
. Ten days prior to enrollment for mycophenolate mofetil
. Four weeks (28 days) prior to enrollment for cyclosporine, methotrexate, cyclophosphamide, thalidomide and dapsone
. Oral and topical corticosteroids must have been tapered as appropriate and discontinued 3 days prior to day of enrollment
. At least 5 terminal half-lives for all biologics including, but not limited to, those listed below; within: i. Four weeks prior to enrollment for etanercept; ii. Eight weeks prior to enrollment for infliximab; iii. Ten weeks prior to enrollment for adalimumab, golimumab, certolizumab, abatacept, and tocilizumab; iv. Six months prior to enrollment for secukinumab.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial tested dusquetide specifically for Behçet's disease and measured the number of oral and genital ulcers — based on what you know about the results, did dusquetide actually reduce ulcer frequency or severity compared to a placebo or standard treatment?
2Since this was a Phase 2 trial and it's now completed, does the available safety data give us enough information to understand the risks of dusquetide, or is there still a lot we don't know because it's early-stage research?
3Given that the trial is completed, is there any published data or findings I could review with you, and do the results suggest dusquetide might move into a larger Phase 3 trial where I could potentially be involved in the future?
4For my specific pattern of Behçet's disease — how often I get oral and genital ulcers and how severe they are — would you say the outcomes this trial was measuring are the most important ones for my situation, or are there other aspects of my disease that matter more?
5Are there existing approved treatments for Behçet's disease that have stronger evidence behind them that we should consider first, before looking at something like dusquetide that is still in early clinical testing?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.